Quantcast

Latest Ampio Pharmaceuticals Inc. Stories

2014-06-30 08:30:15

GREENWOOD VILLAGE, Colo., June 30, 2014 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) today announced that it has started patient enrollment for the MULTIPLE INJECTIONS STUDY using Ampion(TM) for patients with mostly severe or very severe osteoarthritis (mostly severe Kellgren-Lawrence grade 3 and 4) of the knee for which there is no current non-surgical therapy. http://photos.prnewswire.com/prnvar/20120516/MM09116LOGO Ampio's CEO, Mike Macaluso, explained, "This study is...

2014-06-25 08:30:55

GREENWOOD VILLAGE, Colo., June 25, 2014 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) today announced that it has informed the Transplant and Ophthalmology Division of the FDA of its intent to reduce the patient sample size in the OptimEyes Study for the treatment of Diabetic Macular Edema (oral treatment with Optina(TM)). This trial was intended to enroll 450 patients and was powered at 95%. The present enrollment of over 355 patients provides an adequate power of 88%,...

2014-06-05 08:28:34

GREENWOOD VILLAGE, Colo., June 5, 2014 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) today announced the appointment of Gregory A. Gould as Chief Financial Officer, Treasurer, and Corporate Secretary. Mr. Gould, a veteran of the pharmaceutical and life sciences industry, is joining the company effective June 10(th), 2014. Mark McGregor, the company's current CFO, will retire from Ampio Pharmaceuticals following a transition period later this year....

2014-05-27 12:32:32

LONDON, May 27, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:Global Diabetic Nephropathy Market 2014-2018http://www.reportbuyer.com/pharma_healthcare/diseases/global_diabetic_nephropathy_market_2014_2018.html About Diabetic NephropathyDiabetic nephropathy is a disease of the kidney glomerulus, which is caused by high blood sugar. When diabetes damages kidneys, which contain millions of tiny blood vessel clusters (glomeruli) that filter waste from the...

2014-05-21 08:29:02

GREENWOOD VILLAGE, Colo., May 21, 2014 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) today announced that the company is scheduled to present a corporate update at the Jefferies Global Healthcare Conference in New York City. http://photos.prnewswire.com/prnvar/20120516/MM09116LOGO Dr. Vaughan Clift, MD, Ampio's Chief Regulatory and Medical Affairs Officer, and Josh Disbrow, Ampio's Chief Operating Officer and Chief Executive Officer of Ampio subsidiary Luoxis...

2014-04-22 08:33:07

Company Achieves Second Regulatory Clearance for Oxidation-Reduction Potential Platform GREENWOOD VILLAGE, Colo., April 22, 2014 /PRNewswire/ -- Ampio Pharmaceuticals, Inc., (NYSE MKT: AMPE) today announced that its subsidiary Luoxis, an in vitro diagnostics company, has obtained Health Canada Class II Medical Device approval for its RedoxSYS(TM) Diagnostic System, the company's blood-based platform for assessing the level of oxidative stress in the body....

2014-04-21 08:25:38

GREENWOOD VILLAGE, Colo., April 21, 2014 /PRNewswire/ -- Ampio Pharmaceuticals Inc. (NYSE MKT: AMPE) today announced that its wholly-owned subsidiary Vyrix Pharmaceuticals has filed a registration statement on Form S-1 with the United States Securities and Exchange Commission (the "SEC") relating to the proposed initial public offering of its common stock. All of the shares to be sold in the proposed offering will be offered by Vyrix. Vyrix has applied for a listing of its common...

2014-04-10 08:29:34

GREENWOOD VILLAGE, Colo., April 10, 2014 /PRNewswire/ -- Ampio Pharmaceuticals Inc. (NYSE MKT: AMPE) today announced that its wholly-owned subsidiary Vyrix Pharmaceuticals, a specialty pharmaceutical company focused on developing and commercializing late-stage prescription pharmaceuticals to improve men's sexual health, has signed an agreement with Paladin Labs Inc., a leading Canadian specialty pharmaceutical company, to provide exclusive rights to market, sell and distribute...

2014-04-09 08:29:01

GREENWOOD VILLAGE, Colo., April 9, 2014 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) today announced that the results of the 20 weeks extension of the Ampion(TM) SPRING study will be presented by Dr. Nathan Wei, MD of the Arthritis Treatment Center Frederick, MD at the Western Orthopedic Association Conference in July 2014. http://www.woa-assn.org/. This 20-week extension of a multicenter, randomized, vehicle-controlled, double-blind study (NCT01839331) evaluated the safety...

2014-04-02 08:33:12

Regulatory Clearance Enables Commercialization in Europe and other Key Markets GREENWOOD VILLAGE, Colo., April 2, 2014 /PRNewswire/ -- Ampio Pharmaceuticals, Inc., (NYSE MKT: AMPE) today announced that its subsidiary Luoxis, an in vitro diagnostics company, has obtained CE Marking in Europe for its RedoxSYS(TM) Diagnostic System, the company's blood-based platform for assessing the level of oxidative stress in the body. This regulatory clearance allows Luoxis to engage in strategic...


Word of the Day
snash
  • To talk saucily.
  • Insolent, opprobrious language; impertinent abuse.
This word is Scots in origin and probably imitative.